A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Loss of cortical neurons is a key pathological feature in neurodegenerative dementias. Cerebrospinal fluid (CSF) neurofilaments (Nf) are a biomarker for neuronal death and axonal loss. Objective: To perform a meta-analysis to investigate the value of CSF Nf levels for the laboratory-supported differential diagnosis of neurodegenerative dementias. Methods: A systematic review and meta-analysis of studies on CSF Nf heavy (NfH) and light (NfL) levels in patients with dementia. The dementia subgroups analysed were Alzheimer (AD), frontotemporal lobe dementia (FTLD), vascular dementia (SVD), minimal cognitive deficit (MCI). Results: We identified 12 studies on CSF NfH and NfL levels which met the inclusion criteria and 11 were of a quality good enough to be used in this meta-analysis. CSF data was available on 818 patients (306 AD, 106 SVD, 98 FTLD, 25 MCI, 283 controls). Overall CSF NfH and NfL levels were higher in patients with AD, FTLD and SVD when compared to controls. The size of the effect ranged from 0.71 to 1.38. The strongest effect was observed for the comparison of FTLD patients with controls, both for NfL (1.38) and NfH (0.74). CSF NfL were also able to separate patients with FTLD from those with AD. Conclusion: At present we cannot recommend CSF NfH and NfL levels for use as a screening test in the diagnosis of dementia because of the rather small effect size. However, both neurofilament proteins may be of value for targeted investigation of some patients with FTLD, SVD and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
Self-citationRosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
Axonal damage markers in cerebrospinal fluid are increased in ALS
Brettschneider, J., Petzold, A., Süßmuth, S. D., Ludolph, A. C., & Tumani, H. (2006) · Neurology · doi:10.1212/01.wnl.0000203120.85850.54 · Cited by 261
Self-citationNeurofilament protein in cerebrospinal fluid: A marker of white matter changes
Sjögren, M., Blomberg, M., Jonsson, M., Wahlund, L. ‐., Edman, Å., Lind, K., Rosengren, L., Blennow, K., & Wallin, A. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1242 · Cited by 209
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181
Monoclonal Antibodies Selective for Low Molecular Weight Neurofilaments
Norgren, N., Karlsson, J.-E., Rosengren, L., & Stigbrand, T. (2002) · Hybridoma and Hybridomics · doi:10.1089/15368590252917647 · Cited by 81
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationNeurofilaments and Neurofilament Proteins in Health and Disease
Yuan, A., Rao, M. V., Veeranna, & Nixon, R. A. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018309 · Cited by 731
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 486
Self-citationSerum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer, J. D., Woollacott, I. O. C., Dick, K. M., Brotherhood, E., Gordon, E., Fellows, A., Toombs, J., Druyeh, R., Cardoso, M. J., Ourselin, S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003154 · Cited by 432
Self-citation
Metadata
- Authors
- Petzold, A., Keir, G., Warren, J., Fox, N., & Rossor, M. N.
- Venue
- Neurodegenerative Diseases
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 4
- Issue
- 2-3
- Pages
- 185-194
- ISSN
- 1660-2854 (ISSN-L)
- 1660-2862
- OpenAlex
- W1974535033
- Cited by
- 112
- References
- 8
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia. https://app.cochat.ai/papers/10.1159/000101843
- The paper
- Petzold, A., Keir, G., Warren, J., Fox, N., & Rossor, M. N. (2007). A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia. Neurodegenerative Diseases. https://doi.org/10.1159/000101843
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.